BioAgilytix expands GMP analytical capacity in Morrisville and Hamburg

By AI, Created 4:30 PM UTC, May 18, 2026, /AGP/ – BioAgilytix marked one year since expanding GMP testing operations in Morrisville, North Carolina, and Hamburg, Germany, saying the investment is helping sponsors meet rising analytical and regulatory demands. The company says the added capacity supports validation, lot release and stability work as advanced therapeutics move closer to the clinic and commercialization.

Why it matters: - BioAgilytix says advanced therapeutics are increasing demand for GMP-ready analytical testing. - The expanded capacity is meant to help sponsors manage more complex testing, manufacturing support and regulatory readiness. - Stronger GMP infrastructure can reduce variability and support faster, more compliant decisions during development and tech transfer.

What happened: - BioAgilytix highlighted the impact of its strategic GMP investment in Morrisville, North Carolina, and Hamburg, Germany, one year after the expansion. - The company says the expansion established dedicated GMP QC laboratory infrastructure. - The Morrisville site now includes expanded support for GMP analytical testing programs. - Paul Blalock, who recently joined BioAgilytix to lead GMP testing services, said the company is focused on helping sponsors move forward with methods that can withstand regulatory scrutiny.

The details: - BioAgilytix says the Morrisville facility provides GMP testing services, including a biochemistry lab for product characterization testing and expanded bioassay capability. - The Morrisville and Hamburg laboratories operate within a globally aligned infrastructure designed to support consistency across U.S. and European operations. - Over the past year, the company says it has supported clients across multiple modalities as analytical and regulatory requirements have evolved. - BioAgilytix says its GMP testing work is aligned with validation, lot release and stability requirements. - The company says this approach helps lower variability and improve overall program readiness. - Blalock said analytical readiness is a critical component of overall program success.

Between the lines: - The expansion reflects a broader shift in drug development, where analytical testing is moving closer to the center of program execution. - BioAgilytix is positioning GMP capability as a core service, not just a late-stage add-on. - The emphasis on global alignment suggests clients want more consistency across U.S. and European development and manufacturing work.

What’s next: - BioAgilytix says it will keep investing in technology, capacity and scientific leadership to support its global client base. - The company expects demand for scalable, integrated GMP testing solutions to keep rising as clinical pipelines grow and regulatory expectations evolve. - BioAgilytix says it will continue advancing GMP testing capabilities across its laboratories in North America, Europe and Australia.